|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-17 is a crucial effector cytokine, whose production is specifically triggered by IL-23, and it has been shown to be an essential inflammatory mediator in other autoimmune diseases and inflammatory conditions.
|
16386239 |
2005 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-17A is produced primarily by T cells, and is the hallmark cytokine of a newly defined T helper cell subset that appears to be involved in generation of autoimmunity.
|
17027518 |
2006 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Inflammatory cytokines such as interferon (IFN)-gamma, interleukin (IL)-2, tumor-necrosis factor (TNF)-alpha and IL-17 play an important role in the pathogenesis of cell-mediated autoimmune diseases.
|
16782553 |
2006 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-23 induces a third profile, T(H)IL-17, that is dominant in inflammation and autoimmunity.
|
17021762 |
2006 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The importance of the IL-17 family in inflammatory and autoimmune disease is becoming increasingly apparent.
|
16961709 |
2006 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The IL-17/23 axis of inflammation and related molecules may rise as therapeutic targets for treating these and perhaps other autoimmune diseases.
|
17289553 |
2007 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-17A has been implicated in the pathogenesis of autoimmune diseases.
|
17355969 |
2007 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Environmental factors are believed to contribute to the increased prevalence of autoimmune diseases, many of which are due to the activity of T(H)17 T cells, a new helper T-cell subset characterized by the production of the cytokine IL-17.
|
18362914 |
2008 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-17-producing CD4(+) cells, referred to as Th17 cells, have recently been found to play a central role in the development of autoimmune diseases.
|
18453621 |
2008 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The interleukin (IL) -23/IL-17 cytokine axis has been suggested to play an important role in the development of several autoimmune diseases including multiple sclerosis.
|
18180107 |
2008 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Since the IL-23/IL-17 pathway is known to associate with other autoimmune diseases, including rheumatoid arthritis (RA) and systemic sclerosis (SSc), we hypothesised that IL-23R could be a shared susceptibility gene.
|
17606463 |
2008 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Because microglia produce IL-1beta and IL-23, these cytokines may act in an autocrine manner to induce IL-17 expression in microglia, and thereby contribute to autoimmune diseases, such as MS, in the central nervous system.
|
18164424 |
2008 |
|
Autoimmune Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Loss of IL-23/IL-17 by genetic deletion of IL-23/p19 in the Ro52(-/-) mice conferred protection from skin disease and systemic autoimmunity.
|
19635858 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
These results show that IL-27 acts as a negative regulator of the developing IL-17A response in vivo, suggesting a potential therapeutic role for IL-27 in autoimmune diseases.
|
19380822 |
2009 |
|
Autoimmune Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Co-expression of IL-22 and IL-17 has been identified and demonstrated to be involved in the immunopathogenesis of some autoimmune diseases as well as the defense against pathogenic infections in animal studies.
|
19449309 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin 17 (IL-17) plays a critical role in inflammation and autoimmunity.
|
19476435 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-17 is the signature cytokine of recently discovered Th type 17 (Th17) cells, which are prominent in defense against extracellular bacteria and fungi as well as in autoimmune diseases, such as rheumatoid arthritis and experimental autoimmune encephalomyelitis in animal models.
|
19155511 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Th cell cytokines IL-17A and IL-21 have been assigned with pivotal roles in the regulation of such autoimmune diseases.
|
19748983 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The trusted binary system of T(H)1 and T(H)2 has been expanded to include the IL-17-producing T(H)17 cell lineage, which plays a role in immune responses to infectious agents and maintenance of autoimmune diseases.
|
19410687 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Interleukin 17 (IL-17)-producing T helper cells (T(H)-17 cells) are increasingly recognized as key participants in various autoimmune diseases, including multiple sclerosis.
|
19838199 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Studies have suggested involvement of interleukin 17 (IL-17) in autoimmune diseases, although its effect on B cell biology has not been clearly established.
|
19483719 |
2009 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-17 mediates essential inflammatory responses in host defense and autoimmunity.
|
20554964 |
2010 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
These data demonstrate the presence of IL-17(+)IL-9(+) CD4 cells induced by IL-1beta that may play a role in human autoimmune disease.
|
20498357 |
2010 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In support of a causal role for col(V) autoimmunity in the pathogenesis of atherosclerosis, col(V) sensitization of ApoE(-/-) mice on a regular chow diet overcame IL-10-mediated inhibition of col(V) autoimmunity, leading to increased atherosclerotic burden in these mice and local accumulation of IL-17-producing cells, particularly in the col(V)-rich adventitia subjacent to the atheromas.
|
20814021 |
2010 |
|
Autoimmune Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
IL-17A serum concentrations were 5767 ± 2700 pg/ml (mean ± SEM) in sALS patients and 937 ± 927 pg/ml in fALS patients in comparison to 7 ± 2 pg/ml in control subjects without autoimmune disorders (p = 0.008 ALS patients vs. control subjects by Mann-Whitney test).
|
21062492 |
2010 |